Quob Park Estate Ltd cancelled the acquisition of 70% stake in Aiomed GmbH from Biosign Technologies Inc..
In a related deal, Biosign Technologies Inc. (TSXV:BIO) agreed to purchase additional 36.5% stake in Aiomed GmbH from the founder in stock on January 21, 2016. If the divestiture transaction is approved by shareholders, Biosign's remaining ownership will represent 5% of the issued and outstanding shares of Aiomed. The transaction is subject to finalizing a purchase and sale agreement and obtaining regulatory and shareholder approval of Biosign Technologies. The currency has been converted from www.oanda.com as of January 21, 2016.
Quob Park Estate Ltd cancelled the acquisition of 70% stake in Aiomed GmbH from Biosign Technologies Inc. (TSXV:BIO) on April 13, 2016. Biosign Technologies was unable to secure additional Aiomed shares to complete the purchase transaction.